Immune Response News and Research

RSS

Rice University research targets Parkinson's, Huntington's and other proteasomal diseases

Synthetic genetic circuitry created by researchers at Rice University is helping them see, for the first time, how to regulate cell mechanisms that degrade the misfolded proteins implicated in Parkinson's, Huntington's and other diseases.

9 Apr 2014

Herpes simplex viral therapy in conjunction with radiation proves effective in treating malignant gliomas

Researchers at the University of Alabama at Birmingham report a genetically engineered herpes simplex viral therapy is safe when used in conjunction with radiation in the treatment of malignant gliomas, one of the most deadly forms of brain cancer.

9 Apr 2014

Study: VISTA deficiency leads to enhanced immune activation

Researchers at the Geisel School of Medicine at Dartmouth have found that the body's immune system response was enhanced when they disrupted VISTA, a protein that prevents the immune system from overreacting.

8 Apr 2014

SU2C and Farrah Fawcett announce formation of research team dedicated to HPV-related cancers

Stand Up To Cancer (SU2C) and the Farrah Fawcett Foundation, along with the American Association for Cancer Research (AACR), SU2C's Scientific Partner, announced the formation of a research team dedicated to HPV-related cancers during a press event today at the AACR Annual Meeting 2014, held here April 5-9.

8 Apr 2014

UPCI/MWRI researchers to present results of immune gene profile exploring endometriosis and cancer

Some women with endometriosis, a chronic inflammatory disease, are predisposed to ovarian cancer, and a genetic screening might someday help reveal which women are most at risk, according to a University of Pittsburgh Cancer Institute (UPCI) study, in partnership with Magee-Womens Research Institute (MWRI).

7 Apr 2014

New insights provide novel therapeutic approach against cancer

A major discovery that brings a new drug target to the increasingly exciting landscape of cancer immunotherapy was published yesterday by researchers from La Jolla Institute for Allergy and Immunology and their collaborators from other institutes.

7 Apr 2014

Crescendo raises additional £2M ($3.3M) in final close of Series A financing from EMBL Ventures

Crescendo Biologics Limited today announces it has raised a further £2m ($3.3m), from EMBL Ventures, in a final close of its Series A financing. Originally announced in December 2013, the Series A now totals £19.5m. It was led by Imperial Innovations and included new investor Astellas Venture Management. Founding seed investor Sofinnova Partners also contributed significantly to the round.

3 Apr 2014

New research reveals that immunization can trigger distinct change in body odor

Our understanding of the role of body odor in conveying personal information continues to grow. New research from the Monell Chemical Senses Center and the U.S. Department of Agriculture (USDA) reveals that immunization can trigger a distinct change in body odor. This is the first demonstration of a bodily odor change due to immune activation.

3 Apr 2014

Discovery could lead to new therapies for people with celiac disease

Researchers at McMaster University have discovered a key molecule that could lead to new therapies for people with celiac disease, an often painful and currently untreatable autoimmune disorder.

1 Apr 2014

Novel proteins may lead to new ways to combat venereal disease

Researchers at Oregon State University have discovered novel proteins in, or on the surface of the bacteria that causes gonorrhea, which offer a promising new avenue of attack against a venereal disease that is showing increased resistance to the antibiotics used to treat it.

1 Apr 2014

NeuroVive presents clinical data of NVP018 for treatment of chronic hepatitis B infections at EASL

NeuroVive's anti-viral preclinical program, with compound designated NVP018, has generated significant data indicating that NVP018 has the potential to become an effective alternative or addition to current drugs for treating chronic hepatitis B infections.

29 Mar 2014

MD Anderson's Jim Allison honored with 2014 Canada Gairdner International Award

A Canadian institution that annually recognizes seminal medical discoveries selected cancer immunotherapy leader Jim Allison, Ph.D., chair and professor of Immunology at The University of Texas MD Anderson Cancer Center, for one of its 2014 Canada Gairdner International Awards.

29 Mar 2014

$Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM$

Patrys reports final results from PAT-SM6 Phase I/IIa study in patients with refractory or relapsed MM

Patrys Limited, a clinical stage biotechnology company, is pleased to announce the final results from its Phase I/IIa, open-label study in patients with refractory or relapsed multiple myeloma (MM).

28 Mar 2014

Research findings help explain rare genetic disorder that causes immunodeficiency syndrome

IRCM researchers led by Javier M. Di Noia, PhD, uncovered a new function of AID, a crucial enzyme for the immune response. The discovery, recently published by the scientific journal Proceedings of the National Academy of Sciences, helps explain a rare genetic disorder that causes an immunodeficiency syndrome.

28 Mar 2014

Johns Hopkins researchers identify protein that regulates the body's immune response to CMV

Infectious disease specialists at the Johns Hopkins Children's Center have identified a protein that regulates the body's immune response to cytomegalovirus (CMV), a common pathogen that causes lifelong infections and can lead to devastating illness in newborns and those with weakened immune systems.

27 Mar 2014

HIV and Hepatitis C vaccines now closer to reality

Plans for a new type of DNA vaccine to protect against the deadly HIV and Hepatitis C viruses have taken an important step forward, with University of Adelaide researchers applying for a patent based on groundbreaking new research.

26 Mar 2014

ASU scientist selected as 2014 recipient of Lifetime Achievement Award

Roy Curtiss III, a scientist at the Biodesign Institute at Arizona State University, has been selected as the 2014 recipient of the Lifetime Achievement Award from the American Society for Microbiology.

26 Mar 2014

Study examines events that lead to sepsis by Streptococcus pneumoniae

An international team of academics, including Professor Marco Oggioni from the University of Leicester's Department of Genetics, has studied how localised infections can turn into the dangerous systematic disease sepsis - and has identified for the first time through genetic evidence that a single bacteria could be the cause.

24 Mar 2014

Researchers find immune receptor for uric acid crystals

The surface of immune system cells is home to a number of receptors which are able to detect pathogens. As soon as these receptors are activated, inflammation occurs and the body's defense mechanisms kick in. Immune cells also have receptors that regulate or even suppress immunological responses to prevent damage to individual cells.

21 Mar 2014

LSTM and University of Liverpool receive GHIT Fund to target lymphatic filariasis and onchocerciasis

The Liverpool School of Tropical Medicine (LSTM) together with colleagues at the Department of Chemistry (University of Liverpool (UoL)) and Japanese pharmaceutical company Eisai are pleased to announce that they have been awarded a Global Health Innovative Technology (GHIT) Fund to develop new drugs to target lymphatic filariasis and onchocerciasis.

20 Mar 2014